Exclusive

Publication

Byline

Location

Singapore Clinical Trial: A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the ef... Read More


Clinical Trial: Health and Work Ability Following Inpatient Treatment for Stress-related Disorders - Follow-up Study of the HARMODI Cohort

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07757997) titled 'Health and Work Ability Following Inpatient Treatment for Stress-related Disorders - Follow... Read More


Singapore Clinical Trial: A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the ef... Read More


Singapore Clinical Trial: A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigat... Read More


Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants with Obesity or Overweight who are Otherwise Healthy.

Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate t... Read More


Clinical Trial: A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07757087) titled 'A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss ... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy ... Read More


Clinical Trial: Comparison of Performing V-Notes Hysterectomy Under Spinal Anesthesia and General Anesthesia

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758504) titled 'Comparison of Performing V-Notes Hysterectomy Under Spinal Anesthesia and General Anesthesi... Read More


Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, Aug. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, m... Read More


Clinical Trial: Cesarean Delivery Outcomes in Maternal Critical Care

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07759024) titled 'Cesarean Delivery Outcomes in Maternal Critical Care' on July 29. Brief Summary: Cesarean ... Read More